A CROSS-OVER PHARMACOKINETIC AND THROMBOGENICITY STUDY OF A PROTHROMBIN COMPLEX CONCENTRATE AND A PURIFIED FACTOR-IX CONCENTRATE

被引:25
作者
THOMAS, DP
HAMPTON, KK
DASANI, H
LEE, CA
GIANGRANDE, PLF
HARMAN, C
LEE, ML
PRESTON, FE
机构
[1] UNIV WALES HOSP, CTR HAEMOPHILIA, CARDIFF, WALES
[2] ROYAL FREE HOSP, CTR HAEMOPHILIA, LONDON, ENGLAND
[3] CHURCHILL HOSP, CTR HAEMOPHILIA, OXFORD, ENGLAND
[4] INT QUANTITAT CONSULTANTS INC, N HOLLYWOOD, CA USA
[5] ROYAL HALLAMSHIRE HOSP, CTR HAEMOPHILIA, SHEFFIELD, ENGLAND
关键词
PURIFIED FACTOR IX; PCC; HALF-LIFE; RECOVERY; THROMBOGENICITY;
D O I
10.1111/j.1365-2141.1994.tb06738.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A prospective cross-over study was carried out on 19 patients with haemophilia B, comparing the pharmacokinetics of a purified factor IX concentrate prepared by metal chelate affinity chromatography (9MC) with a conventional three-factor prothrombin complex concentrate (9A). The highly purified factor IX concentrate was shown to have a half-life comparable to the PCC; the in vivo recovery of the purified concentrate was significantly greater than that of the complex (P < 0.01). The 20% change in the value of the International Standard for Factor IX Concentrate, introduced in 1988, might have been expected to lower the recovery values. However, the in vivo recovery for both concentrates was somewhat higher than reported previously, particularly in the older literature. In nine patients, serial assays for fibrinopeptide A, prothrombin fragment F1+2 and thrombin-antithrombin complexes (TAT) were performed to assess the potential thrombogenicity of the two concentrates. Evidence was obtained that there was significantly less activation of coagulation following administration of purified factor IX (9MC), as compared to the activation that occurred after the PCC.
引用
收藏
页码:782 / 788
页数:7
相关论文
共 39 条
  • [1] Barrowcliffe T W, 1988, Thromb Haemost, V59, P334
  • [2] STANDARDIZATION AND ASSAY
    BARROWCLIFFE, TW
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1993, 19 (01) : 73 - 79
  • [3] BAUER KA, 1988, BLOOD, V71, P1418
  • [4] BERNTORP E, 1993, THROMB HAEMOSTASIS, V70, P768
  • [5] CLINICAL USE OF FACTOR-IX CONCENTRATES
    BIDWELL, E
    RIZZA, CR
    DIKE, GWR
    SNAPE, TJ
    [J]. THROMBOSIS AND HAEMOSTASIS, 1976, 35 (02) : 488 - 491
  • [6] PROPERTIES OF A HIGHLY PURIFIED HUMAN-PLASMA FACTOR-IX-C THERAPEUTIC CONCENTRATE PREPARED BY CONVENTIONAL CHROMATOGRAPHY
    BURNOUF, T
    MICHALSKI, C
    GOUDEMAND, M
    HUART, JJ
    [J]. VOX SANGUINIS, 1989, 57 (04) : 225 - 232
  • [7] FELDMAN PA, 1993, COLLOQ INSE, V227, P63
  • [8] FELDMAN PA, 1993, THROMB HAEMOSTASIS, V69, P1281
  • [9] GILES AR, 1982, BLOOD, V59, P401
  • [10] COAGULATION FACTOR-IX - SUCCESSFUL SURGICAL EXPERIENCE WITH A PURIFIED FACTOR-IX CONCENTRATE
    GOLDSMITH, JC
    KASPER, CK
    BLATT, PM
    GOMPERTS, ED
    KESSLER, CM
    THOMPSON, AR
    HERRING, SW
    NOVAK, PL
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1992, 40 (03) : 210 - 215